Towards Healthcare
RNA Therapeutics and Vaccines Market to Rise at 87% CAGR till 2034

RNA Therapeutics and Vaccines Market Set for Transformative Growth

Market insights predict, the RNA therapeutics and vaccines industry is expected to grow from USD 0.21 billion in 2024 to USD 107.7 billion by 2034, driven by a CAGR of 87%. The RNA therapeutics and vaccines market is growing as it is an innovative and rapidly emerging field at the forefront of medical research and biotechnology. North America is dominant in the market due to growing research infrastructure and supportive regulatory environments.

Content

  • Last Updated: 28 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The RNA therapeutics and vaccines market stands at USD 0.38 billion in 2025 and is expected to reach USD 107.7 billion by 2034, growing at a CAGR of 87% from 2024 to 2034.

North America is currently leading the RNA therapeutics and vaccines market share by 42% due to a well-developed oncology infrastructure.

Some key players include Pfizer Inc., Novo Nordisk A-S, F. Hoffmann-La Roche AG, Eli Lilly and Company, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

Most vaccines contain a weakened or dead bacterium or virus. However, scientists have developed a new type of vaccine that uses a molecule called messenger RNA (mRNA) rather than part of an actual bacterium or virus.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions